Pure Global
NCT03887637

Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

Real-world Effectiveness and Safety of Treatment With Direct Antiviral Agents (DAAs) in Patients With Chronic Hepatitis C and Cirrhosis in Southern Area of China
Third Affiliated Hospital, Sun Yat-Sen University·ClinicalTrials.gov·drug
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Drug/Device/Intervention
DAAs
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Timeline & enrollment
Phase
N/A
Start date
Mar 30, 2019
End date
Sep 30, 2019
Enrollment
180 participants
Primary outcome

SVR(Sustained Virologic Response)12

Summary

This is a multi-center, open-label clinical study. This study was aimed to assess the
 real-world effectiveness and safety of treatment with listed DAAs in patients with CHC and
 cirrhosis in Southern area of China.

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03887637
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03887637 through Pure Global AI's free database. This phase not specified trial is sponsored by Third Affiliated Hospital, Sun Yat-Sen University and is currently status unknown. The study focuses on Chronic Hepatitis C. Target enrollment is 180 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.